國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Decision making in a world of compar...

Birnbaum, Howard G.

Decision making in a world of comparative effectiveness researcha practical guide /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Decision making in a world of comparative effectiveness researchedited by Howard G. Birnbaum, Paul E. Greenberg.
其他題名:	a practical guide /
其他作者:	Birnbaum, Howard G.
出版者:	Singapore :Springer Singapore :2017.
面頁冊數:	xvi, 289 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Decision making.
電子資源:	http://dx.doi.org/10.1007/978-981-10-3262-2
ISBN:	9789811032622$q(electronic bk.)

Decision making in a world of comparative effectiveness researcha practical guide /
Decision making in a world of comparative effectiveness researcha practical guide /[electronic resource] :edited by Howard G. Birnbaum, Paul E. Greenberg. - Singapore :Springer Singapore :2017. - xvi, 289 p. :ill. (some col.), digital ;24 cm.

I. Introduction -- 1. Introducing Decision Making in a World of Comparative Effectiveness Research -- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies -- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers -- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney -- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company -- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies -- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation -- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER -- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers -- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making? -- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations -- 10. Decision Making by Public Payers -- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials -- 12. Policy Considerations: Ex-U.S. Payers and Regulators -- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective -- 16. Legal Considerations in a World of CER -- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data -- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines -- 18. Challenges in Developing and Assessing CER for Medical Technology -- 19. Evidence Generation Using Big Data: Challenges and Opportunities -- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later -- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry.

In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufactures), government (both public and private payers), as well as decision makers of all levels, both in the US and globally.

ISBN: 9789811032622$q(electronic bk.)

Standard No.: 10.1007/978-981-10-3262-2doiSubjects--Topical Terms:

183849
Decision making.

LC Class. No.: HD30.23

Dewey Class. No.: 658.403

Decision making in a world of comparative effectiveness researcha practical guide /
LDR:04301nmm a2200313 a 4500 001 515428
003 DE-He213
005 20171229171619.0
006 m d
007 cr nn 008maaau
008 180126s2017 si s 0 eng d
020 $a 9789811032622$q(electronic bk.)
020 $a 9789811032615$q(paper)
024 7 $a 10.1007/978-981-10-3262-2 $2 doi
035 $a 978-981-10-3262-2
040 $a GP $c GP
041 0 $a eng
050 4 $a HD30.23
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 658.403 $2 23
090 $a HD30.23 $b .D294 2017
245 0 0 $a Decision making in a world of comparative effectiveness research $h [electronic resource] : $b a practical guide / $c edited by Howard G. Birnbaum, Paul E. Greenberg.
260 $a Singapore : $b Springer Singapore : $b Imprint: Adis, $c 2017.
300 $a xvi, 289 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a I. Introduction -- 1. Introducing Decision Making in a World of Comparative Effectiveness Research -- 2. Perspectives on Decision Making in a World of Comparative Effectiveness: Views from Diverse Constituencies -- II. The Future of CER for Evidence Developers: Perspectives from Pharmaceutical Decision Makers -- 3. Perspectives on the Use of CER by Life Sciences Executives: An Interview with Mike Bonney -- 4. Perspectives on the Use of CER by Life Sciences Executives: An Interview with a Senior Executive at an International Life Science Company -- 5. CER: A Pharmaceutical Industry Perspective on Outlook, Dilemmas, and Controversies -- 6. Impact of Comparative Effectiveness Research on Drug Development Strategy and Innovation -- 7. Pricing of Pharmaceuticals: Current Trends and Outlook, and the Role of CER -- III. Evolving Stakeholder Considerations: Patients, Physicians, Regulators and Payers -- 8. Are Real-World Data and Evidence Good Enough to Inform Healthcare and Health Policy Decision Making? -- 9. Translating CER Evidence to Real-World Decision-Making: Some Practical Considerations -- 10. Decision Making by Public Payers -- 11. Patient and Stakeholder Engagement in Designing Pragmatic Clinical Trials -- 12. Policy Considerations: Ex-U.S. Payers and Regulators -- 13. Perspectives on the Common Drug Review (CDR) Process at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 14. Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in Health (CADTH) -- 15. Challenges and Opportunities in the Dissemination of CER Information to Physicians and Payers: A Legal Perspective -- 16. Legal Considerations in a World of CER -- IV. Emerging Challenges, Methods and Applications of CER: Real-world and Big Data -- 17. Application of CER to Promote Adherence to Clinical Practice Guidelines -- 18. Challenges in Developing and Assessing CER for Medical Technology -- 19. Evidence Generation Using Big Data: Challenges and Opportunities -- 20. Indirect Comparisons Using Clinical Trial Data: 5 Years Later -- 21. Decision-Making with Machine Learning in Our Modern, Data-Rich Healthcare Industry.
520 $a In the past decade there has been a worldwide evolution in evidence-based medicine that focuses on real-world Comparative Effectiveness Research (CER) to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decision making using the results of analysis and interpretation of CER. Decision Making in a World of Comparative Effectiveness contains chapters by senior industry executives, key opinion leaders, accomplished researchers, and leading attorneys involved in resolving disputes in the life sciences industry. The book is aimed at 'users' and 'decision makers' involved in the life sciences industry rather than those doing the actual research. This book appeals to those who commission CER within the life sciences industry (pharmaceutical, biologic, and device manufactures), government (both public and private payers), as well as decision makers of all levels, both in the US and globally.
650 0 $a Decision making. $3 183849
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Pharmacoeconomics and Health Outcomes. $3 696758
650 2 4 $a Health Economics. $3 522380
650 2 4 $a Statistics for Life Sciences, Medicine, Health Sciences. $3 274067
650 2 4 $a Pharmaceutical Sciences/Technology. $3 338426
700 1 $a Birnbaum, Howard G. $3 785877
700 1 $a Greenberg, Paul E. $3 785878
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-3262-2
950 $a Medicine (Springer-11650)